Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomize
about
Psychosocial interventions for people with both severe mental illness and substance misusePhysical health care monitoring for people with serious mental illnessDaily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users.Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial.Ethylglucuronide in maternal hair as a biomarker of prenatal alcohol exposure.Effect of high-potency cannabis on corpus callosum microstructure.Patterns of Substance Use During Cognitive Enhancement Therapy: An 18-Month Randomized Feasibility Study.Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial.The Effect of Changes in Cannabis Exposure on Psychotic Symptoms in Patients With Comorbid Cannabis Use Disorder.Clearing the haze: the complexities and challenges of research on state marijuana laws.World Health Organization disability assessment schedule 2.0: An international systematic review.Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial.The effects of cannabis use expectancies on self-initiated cannabis cessation.Feasibility of a group cessation program for co-smokers of cannabis and tobacco.A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial.Appetitive startle modulation in the human laboratory predicts Cannabis craving in the natural environment.Subjective cannabis effects as part of a developing disorder in adolescents and emerging adults.Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study.
P2860
Q24197576-5E3E1107-9AB0-4C6F-80CE-8A8738BA84E0Q24236698-99E83E57-0C0E-4A4C-8CFB-4F62BA851438Q34322915-DB62BE30-A024-492E-BDE5-8E641872F628Q35019827-43A38B05-CF8A-400B-9105-422E7630CE1BQ36012244-8700017F-9196-482E-99EF-9D7794FF7BC6Q36583662-84E5BE01-13EE-4747-973C-4799CEFA8F92Q36815675-132A1EC4-A95A-4AA2-8ABE-6D1773706722Q38389409-C6C055DF-5493-4996-84A6-27AB0B4F50ECQ38882225-A5F9AC45-F04D-41B4-895A-DE25E9EB2C24Q38977158-50E9B2CA-8CD1-46A9-A94C-7C0B3092D602Q39002028-DE30C0D1-D7E9-4D46-A8B1-95F38101760FQ44530576-2A8EE59D-8B52-42D4-8FCE-2735DA1C600BQ45327251-93F90335-6F87-48DE-B614-DEB1911B0E8FQ48116612-757B8B8C-A933-4119-897B-E1A08907D13AQ48635203-DB35A73F-4B70-4CDC-8484-679B44153EFAQ52317398-1D844D3E-7467-4F48-A6FF-EB2FABD31C55Q53407016-A16D47B5-BFF2-49E7-8BB8-A35E13C761FAQ54976153-6713D36D-12DC-4E65-8592-32B78891B6DA
P2860
Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomize
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Correlations and agreement bet ...... ttending the CapOpus randomize
@en
Correlations and agreement between delta-9-tetrahydrocannabinol
@nl
type
label
Correlations and agreement bet ...... ttending the CapOpus randomize
@en
Correlations and agreement between delta-9-tetrahydrocannabinol
@nl
prefLabel
Correlations and agreement bet ...... ttending the CapOpus randomize
@en
Correlations and agreement between delta-9-tetrahydrocannabinol
@nl
P2093
P2860
P921
P1433
P1476
Correlations and agreement bet ...... ttending the CapOpus randomize
@en
P2093
Allan Fohlmann
Anne-Mette Larsen
Mikkel Arendt
P2860
P304
P356
10.1111/J.1360-0443.2011.03757.X
P407
P577
2012-02-13T00:00:00Z